Li Teng, Zhang Hong-Bing, Meng Jia-Min, Yuan Bo, Lin Wen-Juan, Feng Yue, Chen Xiao-Dong
First Affiliated Hospital of Northwest University, Northwest University, Xi'an 710069, Shaanxi Province, China.
College of Life Sciences, Northwest University, Xi'an 710069, Shaanxi Province, China.
Int J Ophthalmol. 2021 Apr 18;14(4):489-496. doi: 10.18240/ijo.2021.04.02. eCollection 2021.
To investigate YM155's effect on retinal pigment epithelium (RPE) cells' viability and the potential regulatory mechanisms.
Human immortalized RPE cell lines (ARPE-19 cell line) were processed with YM155 and epidermal growth factor (EGF). ARPE-19 cell viability was detected by methyl thiazolyl tetrazolium assay, and apoptosis was tested by flow cytometry assay. ARPE-19 cell proliferation was assessed with bromodeoxyuridine tagged incorporation assay, and migration ability was evaluated a wound-healing assay. Epidermal growth factor receptor (EGFR)/MAPK pathway proteins were tested immunoblotting. EGFR localization was examined by immunofluorescence assay.
YM155 suppressed ARPE-19 cells' viability in a time and concentration-dependent manner. A high dose of YM155 caused a small amount of ARPE-19 cell death. YM155 significantly diminished the ARPE-19 cells' proliferative and migrative capacity. YM155 down-regulated total EGFR and phosphorylated external signal-regulated protein kinase (ERK), and it up-regulated the phosphorylation of P38MAPK and c-Jun N-terminal kinase (JNK). YM155 induced endocytosis of EGFR in ARPE-19 cell. YM155 also attenuated EGF-induced ARPE-19 cells' proliferative and migrative capacity. Moreover, YM155 significantly decreased the expression of phosphorylated EGFR and ERK after treated by EGF.
YM155 inhibits RPE cell survival, the cell proliferative and migrative capacity, and it effectuates a small amount of cell death through the EGFR/MAPK signaling pathway. YM155 might, therefore, be an agent to prevent and treat abnormal RPE cell survival in proliferative vitreoretinopathy.
研究YM155对视网膜色素上皮(RPE)细胞活力的影响及其潜在调控机制。
用YM155和表皮生长因子(EGF)处理人永生化RPE细胞系(ARPE - 19细胞系)。采用甲基噻唑基四氮唑蓝法检测ARPE - 19细胞活力,通过流式细胞术检测细胞凋亡。用溴脱氧尿苷掺入法评估ARPE - 19细胞增殖,采用伤口愈合试验评估细胞迁移能力。通过免疫印迹法检测表皮生长因子受体(EGFR)/丝裂原活化蛋白激酶(MAPK)信号通路蛋白。用免疫荧光法检测EGFR定位。
YM155以时间和浓度依赖性方式抑制ARPE - 19细胞活力。高剂量YM155导致少量ARPE - 19细胞死亡。YM155显著降低ARPE - 19细胞的增殖和迁移能力。YM155下调总EGFR和磷酸化的细胞外信号调节蛋白激酶(ERK),上调P38MAPK和c - Jun氨基末端激酶(JNK)的磷酸化水平。YM155诱导ARPE - 19细胞中EGFR的内吞作用。YM155还减弱了EGF诱导的ARPE - 19细胞的增殖和迁移能力。此外,在EGF处理后,YM155显著降低磷酸化EGFR和ERK的表达。
YM155抑制RPE细胞存活、细胞增殖和迁移能力,并通过EGFR/MAPK信号通路导致少量细胞死亡。因此,YM155可能是一种预防和治疗增殖性玻璃体视网膜病变中RPE细胞异常存活的药物。